ARTA
SYRS

A.R.T. Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

A.R.T. Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,946
Closed -$204K – 1051
2019
Q4 		$204K Buy
+2,946
New +$179K 0.01% 1152
2019
Q3 		– Sell
-1,283
Closed -$119K – 1779
2019
Q2 		$119K Buy
+1,283
New +$89.3K 0.01% 1170
2018
Q3 		– Sell
-1,100
Closed -$112K – 1769
2018
Q2 		$112K Buy
+1,100
New +$136K ﹤0.01% 1288

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

A.R.T. Advisors's SYRS Position: Q1 2020 in Review

A.R.T. Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2020, closing a stake of 2,946 shares — an estimated $204K sold.

A.R.T. Advisors first reported a position in SYRS in Q2 2018 and held it in 3 quarters. The position peaked at $204K in Q4 2019. 64 funds tracked by Wall St. Rank hold SYRS as of Q1 2020.

  • A.R.T. Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 2,946 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $204K.
  • A.R.T. Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
  • A.R.T. Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $204K in Q4 2019.
  • 64 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.